Download The Findit App

Share Your Posts On These Major Social Networks

Instatag Your Posts to Instagram Facebook + Twitter

News

MissionIR News - International Stem Cell Corp. (ISCO): Benefits of Stem Cells Outlined in Israel/California Collaboration

Atlanta 3/4/2016 8:00:00 PM

MissionIR would like to highlight International Stem Cell Corporation (OTCBB: ISCO), researching the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). The company is focused on using these stem cells to treat diseases of the eye, the nervous system, and the liver, where cell therapy has been proven clinically yet is limited by the availability of safe immune-matched human cells or tissue.

In the company’s news:

In a recent article on the Jewish Journal website (http://dtn.fm/DhxK8), doctors, dignitaries and officials representing Israel and California convened at Cedars-Sinai Medical Center on February 8, 2016, to witness the signing of an agreement between Israel’s Ministry of Science and the California Institute for Regenerative Medicine (CIRM) to collaborate on stem cell research. It follows a 2014 Memorandum of Understanding to promote collaboration and innovation between Israel and California.

“Stem cell research is a cutting-edge field full of promise and opportunity. Who better to forge new ground together than the State of Israel and the State of California?” Israeli Minister of Science, Technology and Space Ofir Akunis said in the article. “Both are hotbeds of innovation, medical research and technological invention and have a strong commitment to science as a means to improve the lot of all humanity … creating a brighter future for us all.”

International Stem Cell Corp. (OTCQB: ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. The company’s stem cells present superior immune matching capabilities and can be used in millions of people, regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

Stem cells are the future of medicine. Companies like International Stem Cell Corp. are on the front lines of this invaluable research, constantly looking for new ways stem cells can improve our quality of life by treating and eliminating diseases of the central nervous system (i.e. Parkinson’s disease), the liver, and the eye. The technology is getting better every day, and more people are coming around to at least giving it a look. The company has an ethical and moral purpose along with the potential to capitalize on a huge revenue stream.

The combined direct and indirect costs of Parkinson’s disease (PD), including treatment, social security payments and lost income from inability to work, is estimated to be nearly $25 billion per year in the U.S. alone. Medication costs for an individual person with PD average $2,500 a year, and therapeutic surgery can cost up to $100,000 dollars per patient.

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit http://MissionIR.com

To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR

To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR

Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

More News

MissionIR News - International Stem Cell Corporation (ISCO) has a Place in the SAGE Encyclopedia of Stem Cell Research


Released On: 4/8/2016
Views: 3584

MissionIR News - eXp Realty International Corporation (EXPI) Attains Exclusive Rights to VirBELA Platform within Real Estate Industry


Released On: 4/7/2016
Views: 4366

MissionIR News - Moxian (MOXC): Social Media is a Necessity for Small Businesses Too


Released On: 3/31/2016
Views: 3328

MissionIR News - OurPet’s Company (OPCO) Reaches Favorable Settlement in Patent Infringement Case


Released On: 3/24/2016
Views: 2704

MissionIR News - Content Checked Holdings (CNCK) Reminds Us That You Are What You Eat


Released On: 3/17/2016
Views: 2249

MissionIR News - Oakridge Global Energy Solutions, Inc. (OGES) Promises Your Machine Will Start Every Time with its Lithium-Ion Battery


Released On: 3/11/2016
Views: 2039

MissionIR News - International Stem Cell Corp. (ISCO): Benefits of Stem Cells Outlined in Israel/California Collaboration


Released On: 3/4/2016
Views: 2393

MissionIR News - OurPet’s Company (OPCO) Adapting to a Constantly Changing Pet Products Industry with Innovation


Released On: 3/3/2016
Views: 2086

MissionIR News - Avoid Getting Poisoned with the Help of a Personal Food Taster from Content Checked Holdings (CNCK)


Released On: 2/23/2016
Views: 3438

MissionIR News - Oakridge Global Energy Solutions, Inc. (OGES) Ushering in a New Era in Battery Manufacturing


Released On: 2/12/2016
Views: 2418

MissionIR News - International Stem Cell Corp. (ISCO) Eyes Growth through Partnerships to Develop Therapeutic and Biomedical Products Worldwide


Released On: 2/10/2016
Views: 2121

MissionIR News - Torchlight Energy Resources, Inc. (TRCH) Moving Forward with Planning of Next Phase of Drilling on Orogrande Project


Released On: 2/9/2016
Views: 2260

MissionIR News - Content Checked Holdings, Inc. (CNCK) Updates Investors through Release of CEO’s Letter to Shareholders


Released On: 1/20/2016
Views: 4084

MissionIR News - International Stem Cell Corporation (ISCO) – Florey Clinical Service Agreement Expected to Deliver Results Later this Year


Released On: 1/14/2016
Views: 4547

MissionIR News - Moxian (MOXC) Announces Launch of New Subsidiary in Beijing


Released On: 1/5/2016
Views: 2770

MissionIR News - Elephant Talk Communications (ETAK) Initiates Restructuring of Global Business Operations with Executive and Board Appointments


Released On: 12/18/2015
Views: 9087

MissionIR News - International Stem Cell Corp. (ISCO) Has a Broad Pipeline of Targets


Released On: 12/9/2015
Views: 2549

MissionIR News - Oakridge Global Energy Solutions (OGES) is Flying High in the Drone Market


Released On: 12/3/2015
Views: 2983

Load More wait